Can-Fite BioPharma (CANF) announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US patent office. Namodenoson is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis, MASH, advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted, Namodenoson had a very favorable safety profile when administered orally. The patent application No. 17/309,952 entitled “An A3 adenosine receptor ligand for use for achieving a fat loss effect”, has been accepted by the US Patent Office, will be issued on February 2nd and expires in 2042.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- D. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’
- Can-Fite’s Namodenoson to be Highlighted for Liver Protection at ASCO Symposium
- Can-Fite BioPharma announces presentation on namodenoson
- Biotech Alert: Searches spiking for these stocks today
- Can-Fite BioPharma’s Namodenoson Shows Promising Cancer Results